What is the difference between Vellux Botulinum and other neurotoxins?

Molecular Structure and Manufacturing Process

At its core, the primary difference between vellux botulinum and other neurotoxins lies in its specific molecular formulation and the proprietary manufacturing process used to create it. All botulinum neurotoxin type A products, including well-known names like Botox, Dysport, and Xeomin, share the same fundamental mechanism: they block the release of acetylcholine at the neuromuscular junction, leading to temporary muscle relaxation. However, the exact protein structure surrounding the active neurotoxin core, the presence of complexing proteins, and the purification techniques result in distinct pharmacological profiles.

Vellux is characterized as a “naked” or “pure” neurotoxin, similar to Xeomin (incobotulinumtoxinA). This means the formulation contains the 150kDa neurotoxin without the accessory proteins (hemagglutinin and non-hemagglutinin proteins) that are present in the natural clostridium botulinum bacterium. In contrast, Botox (onabotulinumtoxinA) and Dysport (abobotulinumtoxinA) include these complexing proteins in their final formulation. The significance of this difference is a topic of ongoing research, but the “naked” nature of Vellux is theorized to potentially reduce the risk of the body developing neutralizing antibodies, which can lead to treatment resistance over time. The manufacturing involves a highly controlled fermentation and a series of purification steps, including chromatography, to achieve a specific potency and purity profile.

Unit Potency and Dosing Conversion

One of the most critical and practical differences for practitioners is the unit potency. It is a common misconception that units are interchangeable between brands. Each product has its own unique definition of a “unit” based on the specific assay used to measure its biological activity. The mouse LD50 assay is the standard, but differences in the assay methodology mean that 1 unit of Vellux is not biologically equivalent to 1 unit of Botox, Dysport, or any other neurotoxin.

While direct 1:1 conversion is not recommended and dosing must be individualized based on the patient’s anatomy and the clinician’s experience, general conversion ratios have been established through clinical use and studies. The following table provides a reference for experienced practitioners, emphasizing that these are approximations and not strict rules.

For example, if a treatment plan calls for 20 units of Botox in the glabellar lines (frown lines), a practitioner using Vellux might start with a very similar dose, perhaps 20 units, while carefully assessing the patient’s response. However, using Dysport for the same indication would likely require a dose in the range of 50-60 units. This non-interchangeability is why thorough training and familiarity with a specific product are paramount for patient safety and optimal outcomes.

Diffusion Characteristics and Clinical Implications

Diffusion refers to how far the neurotoxin spreads from the injection site after it is administered. This property is influenced by the molecular size (with or without complexing proteins), the reconstitution volume (how much liquid the powder is mixed with), and injection technique. The diffusion profile is a double-edged sword and significantly impacts the clinical strategy.

Products with a larger molecular weight or those reconstituted with a larger volume of saline are generally thought to have a greater potential for diffusion. Dysport is often cited as having a broader diffusion radius compared to Botox. This can be advantageous when treating larger muscle areas, like the platysmal bands in the neck, where a wider area of effect is desirable. However, in precise areas like the crow’s feet around the eyes, excessive diffusion can lead to unwanted effects, such as drooping of the eyelid (ectropion) or a smile that is affected.

Vellux, with its pure 150kDa neurotoxin structure, is believed to have a more controlled and localized diffusion pattern, similar to Botox and Xeomin. This makes it particularly suitable for aesthetic treatments that require high precision. A practitioner can target very specific muscles—like the corrugator supercilii responsible for frown lines—with a reduced likelihood of affecting adjacent muscles. This precision contributes to a more natural-looking result and enhances the safety profile in delicate facial areas.

Onset of Action and Duration of Effect

Patients are always keen to know two things: how quickly will it work, and how long will it last? While there is individual variation, differences between products can be observed. The onset of action typically begins within 24-72 hours, with the full effect becoming apparent between 5 to 14 days post-injection.

For Vellux, clinical studies and user reports indicate an onset and duration profile that is competitive with established market leaders. Patients can generally expect to see initial results within 2-3 days, with peak effect at around 10-14 days. The duration of muscle relaxation is typically in the range of 3-4 months for most patients. This is comparable to the 3-4 month duration seen with Botox and Xeomin. Dysport is sometimes noted for a marginally faster onset by a day or two in some patients, but the overall duration remains similar.

It’s important to understand that duration is highly patient-specific. Factors such as the individual’s metabolism, the strength of the targeted muscles, the dose administered, and the frequency of treatments all play a more significant role than the brand of neurotoxin itself. A patient receiving their first treatment may have a shorter duration (e.g., 2-3 months) than a patient who has been receiving regular treatments for years, as the muscles can become trained to a more relaxed state.

Reconstitution, Storage, and Handling

The practicalities of handling these products in a clinical setting reveal another layer of difference. Most botulinum toxin type A products are supplied as a lyophilized (freeze-dried) powder that needs to be reconstituted with sterile, preservative-free saline before injection. The concentration achieved (e.g., 100 units/mL vs. 50 units/mL) can influence the diffusion, as mentioned earlier.

A key differentiator for Vellux is its storage recommendation. Like Xeomin, Vellux is stable at room temperature (up to 25°C or 77°F) before reconstitution. This is a significant logistical advantage over products like Botox and Dysport, which require refrigeration (2°C to 8°C) from the moment they are manufactured until they are reconstituted. The room-temperature stability simplifies shipping, storage, and inventory management for clinics, reducing the risk of potency loss due to accidental temperature excursions. After reconstitution, all neurotoxins must be refrigerated and used within a short window, typically 24 hours, to ensure sterility and potency.

Immunogenicity and Long-Term Use

The potential for the body to develop neutralizing antibodies is a consideration for any biologic medication. When antibodies form, they bind to the neurotoxin, rendering it ineffective and leading to treatment failure. The risk is generally low (estimated at less than 1-2% for cosmetic doses) but is higher with larger, more frequent doses, as used in therapeutic settings for conditions like cervical dystonia.

The theory behind “naked” toxins like Vellux and Xeomin is that by removing the complexing proteins—which are not necessary for the therapeutic effect but are highly antigenic (likely to provoke an immune response)—the overall antigenic load is reduced. This may potentially lower the risk of antibody development compared to formulations that contain these proteins. While long-term data for Vellux is still accumulating, the principle is derived from the established profile of incobotulinumtoxinA. For patients who require long-term management or those who may be concerned about treatment resistance, this molecular characteristic represents a significant point of differentiation.

Regulatory Approvals and Global Availability

The landscape of regulatory approvals is a final, crucial point of differentiation. Botox, Dysport, and Xeomin have been on the market for many years and have received approval from major regulatory bodies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for a wide range of both cosmetic and therapeutic indications.

Vellux, being a newer entrant, has a different approval footprint. It has received CE marking in Europe and approvals in numerous countries across Asia and South America for cosmetic use. The specific indications and approved doses can vary by country. This regulatory status means that while it is a well-studied and approved product in many markets, its global recognition and the breadth of clinical data supporting its use for a wide array of conditions are not yet as extensive as those of the pioneering brands. Practitioners must operate within the regulatory framework of their specific country when selecting a product for treatment.